MK-7264 Drug Insight

“MK-7264 Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about MK-7264 for Chronic Refractory Cough (CRC) in the seven major markets. A detailed picture of the MK-7264 for chronic refractory cough in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the MK-7264 for chronic refractory cough. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the MK-7264 market forecast analysis for chronic refractory cough in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic refractory cough.

Drug Summary

MK-7264 (gefapixant), being developed by Merck & Co for the treatment of RCC or UCC. Also known as AF-219, it is an investigational, non-narcotic, orally-administered, selective P2X3 receptor antagonist that prevents ATP binding.

Airway inflammation, irritation, and mechanical stress or injury cause chemical stimuli, including ATP, to be produced from the cells that line the airways. P2X3 receptors are one of the receptor types found on sensory nerve fibers, predominantly C fibers, in the airway lining. These purinergic, ligand-gated ion channel, upon binding with extracellular ATP from airway inflammation, activates vagal C-fibre sensory neurons, thus initiating the cough reflex. Blockade of this extracellular ATP binding to P2X3 receptors reduces sensory C fiber activation and subsequently, coughing. Thus MK-7264 exerts its antagonism via negative allosteric modulation

In 2020, Merck completed Phase III trials for MK-7264 and based on its result submitted a NDA for the approval of MK-7264. The drug has received approval in Japan. In January 2022, the FDA issued a CRL regarding Merck’s NDA for MK-7264 and requested additional information related to the measurement of efficacy. Currently, Merck is is performing additional analyses and anticipates submitting this information to the FDA in the first half of 2023 in response to the CRL. The review period in the EU has also been extended pending the receipt of additional information from the Company. The Company plans to submit the information to the EMA in the first half of 2023.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the MK-7264 description, mechanism of action, dosage and administration, research and development activities in chronic refractory cough.
• Elaborated details on MK-7264 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the MK-7264 research and development activities in chronic refractory cough across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around MK-7264.
• The report contains forecasted sales of for chronic refractory cough till 2032.
• Comprehensive coverage of the late-stage emerging therapies for chronic refractory cough.
• The report also features the SWOT analysis with analyst views for MK-7264 in chronic refractory cough.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

MK-7264 Analytical Perspective by DelveInsight

In-depth MK-7264 Market Assessment

This report provides a detailed market assessment of MK-7264 for chronic refractory cough in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

MK-7264 Clinical Assessment

The report provides the clinical trials information of MK-7264 for chronic refractory cough covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for chronic refractory cough is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MK-7264 dominance.
• Other emerging products for chronic refractory cough are expected to give tough market competition to MK-7264 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MK-7264 in chronic refractory cough.
• Our in-depth analysis of the forecasted sales data of MK-7264 from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the MK-7264 in chronic refractory cough.

Key Questions

• What is the product type, route of administration and mechanism of action of MK-7264?
• What is the clinical trial status of the study related to MK-7264 in chronic refractory cough and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MK-7264 development?
• What are the key designations that have been granted to MK-7264 for chronic refractory cough?
• What is the forecasted market scenario of MK-7264 for chronic refractory cough?
• What are the forecasted sales of MK-7264 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to MK-7264 for chronic refractory cough?
• Which are the late-stage emerging therapies under development for the treatment of chronic refractory cough?